Novacyl RoussillonJune 27, 2016

FDA 483 - Novacyl Roussillon - June 27, 2016

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Novacyl Roussillon

Record Details

Novacyl, an active pharmaceutical manufacturer in Roussillon, France, received two observations during an FDA inspection in June 2016. The firm failed to thoroughly review batch failures related to impurity specifications for an API, and also had issues with equipment maintenance, including leaks and malfunctions, which contributed to product impurity failures. These observations indicate deficiencies in quality control and equipment management practices.

Company: Novacyl Roussillon
Inspection Date: June 27, 2016
Product Type: Drugs
Office: Office of Inspections and Investigations
Person: Russell J. Glapion

Open in Dashboard

ID · a2aae6a4-8c12-4fb5-b36f-b3ff7771f9ed